![]()
|
|
||||||||
J. Biol. Chem., Vol. 280, Issue 45, 37725-37731, November 11, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1
1



2
From the
Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129,
Telethon Institute of Genetics and Medicine, 80131 Naples, Italy, ¶Abramson Comprehensive Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, the ||Department of Clinical and Experimental Medicine, Pharmacology Section, Perugia University Medical School, Perugia, Italy, **Cancer Biology and Genetics Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, and the 
Department of Biochemistry, University of Lausanne, Epalinges 1066 CH, Switzerland
Glucocorticoid-induced tumor necrosis factor receptor (GITR) is a member of the tumor necrosis factor receptor superfamily, is expressed in T lymphocytes, and exerts an anti-apoptotic function in these cells. We reported that GITR is also highly expressed in the skin, specifically in keratinocytes, and that it is under negative transcriptional control of p21Cip1/WAF1, independently from the cell cycle. Although GITR expression is higher in p21-deficient keratinocytes and skin, it is down-modulated with differentiation and in response to UVB. The combined analysis of keratinocytes with increased GITR expression versus normal keratinocytes and skin of mice with a disruption of the GITR gene indicates that this protein protects keratinocytes from UVB-induced apoptosis both in vitro and in vivo.
Received for publication, July 21, 2005 , and in revised form, August 15, 2005.
* This work was supported by National Institutes of Health Grants AR39190, CA16038, and CA73796 and a grant from the Swiss National Foundation (to G. P. D.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Both authors contributed equally to this work.
2 To whom correspondence should be addressed: Dept. of Biochemistry, University of Lausanne, Chemin de Boveresses 155, CH-1066 Epalinges, Switzerland. Tel.: 41-21-692-5720; Fax: 41-216925705; E-mail: gdotto{at}partners.org.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
O. Stojadinovic, B. Lee, C. Vouthounis, S. Vukelic, I. Pastar, M. Blumenberg, H. Brem, and M. Tomic-Canic Novel Genomic Effects of Glucocorticoids in Epidermal Keratinocytes: INHIBITION OF APOPTOSIS, INTERFERON-{gamma} PATHWAY, AND WOUND HEALING ALONG WITH PROMOTION OF TERMINAL DIFFERENTIATION J. Biol. Chem., February 9, 2007; 282(6): 4021 - 4034. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Ritchlin and F Tausk A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents. Ann Rheum Dis, December 1, 2006; 65(12): 1541 - 1544. [Full Text] [PDF] |
||||
![]() |
V. Devgan, B.-C. Nguyen, H. Oh, and G. P. Dotto p21WAF1/Cip1 Suppresses Keratinocyte Differentiation Independently of the Cell Cycle through Transcriptional Up-regulation of the IGF-I Gene J. Biol. Chem., October 13, 2006; 281(41): 30463 - 30470. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Mak, M.-H. Chen, T. F. Day, P.-T. Chuang, and Y. Yang Wnt/{beta}-catenin signaling interacts differentially with Ihh signaling in controlling endochondral bone and synovial joint formation Development, September 15, 2006; 133(18): 3695 - 3707. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Gartel Is p21 an oncogene? Mol. Cancer Ther., June 1, 2006; 5(6): 1385 - 1386. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |